3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
41
Stomach Neoplasms
3
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Rhabdomyosarcoma
1
Pleuropulmonary blastoma
1
Patient Preference
1
Pancreatic Neoplasms
1
Neurofibrosarcoma
1
Neuroblastoma
1
Multiple Myeloma
1
Lymphoma
1
Inflammatory Breast Neoplasms
1
Hematologic Neoplasms
1
HER2-positive Breast Cancer
1
HER2 Positive Breast Cancer
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
vandetanib
7
Sorafenib
6
Magnetic Resonance Spectroscopy
6
lenvatinib
5
cabozantinib
5
Sunitinib
4
Iodine-131
4
selpercatinib
3
AZD 6244
3
trametinib
2
tipifarnib
2
durvalumab
2
dabrafenib
2
alectinib
2
Triiodothyronine
2
Thyroxine
2
Thyrotropin Alfa
2
Paclitaxel
2
Nivolumab
2
Ipilimumab
2
Fluorodeoxyglucose F18
2
Everolimus
2
Bortezomib
2
Axitinib
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
tremelimumab
1
temsirolimus
1
tanespimycin
1
sapanisertib
1
romidepsin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Thyroid Neoplasms
×
Ado-Trastuzumab Emtansine
×
Clear all
No trials found.